M K Ito

Summary

Publications

  1. ncbi request reprint Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol
    M K Ito
    Southern California Clinical Experience Program, School of Pharmacy and Health Sciences, University of the Pacific UOP, Stockton, USA
    Am J Health Syst Pharm 58:1734-9. 2001
  2. ncbi request reprint The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin
    Matthew K Ito
    Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    Ann Pharmacother 38:277-85. 2004
  3. ncbi request reprint Advances in the understanding and management of dyslipidemia: using niacin-based therapies
    Matthew K Ito
    University of the Pacific, Thomas J Long School of Pharmacy and Health Sciences, 3350 La Jolla Village Drive, San Diego, CA 92161 0002, USA
    Am J Health Syst Pharm 60:S15-21; quiz S25. 2003
  4. ncbi request reprint Fenofibrate and warfarin interaction
    M A Aldridge
    University of Pacific, Stockton, California, and Veterans Administration San Diego Healthcare System, USA
    Pharmacotherapy 21:886-9. 2001
  5. ncbi request reprint The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1
    M K Ito
    University of the Pacific School of Pharmacy, Stockton, USA
    J Clin Pharmacol 41:779-82. 2001
  6. ncbi request reprint The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events
    M K Ito
    Department of Pharmacy Practice, School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    J Cardiovasc Pharmacol Ther 6:129-35. 2001
  7. ncbi request reprint Colesevelam hydrochloride: a novel bile acid-binding resin
    M A Aldridge
    School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    Ann Pharmacother 35:898-907. 2001
  8. ncbi request reprint Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
    Matthew K Ito
    University of California, San Diego School of Medicine, La Jolla, California, USA
    Pharmacotherapy 26:85S-97S; discussion 98S-101S; quiz 106S-108S. 2006
  9. ncbi request reprint Niacin-based therapy for dyslipidemia: past evidence and future advances
    Matthew K Ito
    Southern California Clinical Experience Program, Thomas J Long School of Pharmacy, University of the Pacific, Stockton, USA
    Am J Manag Care 8:S315-22. 2002
  10. ncbi request reprint Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia
    Eric K Gupta
    University of the Pacific Thomas J Long School of Pharmacy and Health Sciences, Stockton, California, USA
    Heart Dis 4:124-37. 2002

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol
    M K Ito
    Southern California Clinical Experience Program, School of Pharmacy and Health Sciences, University of the Pacific UOP, Stockton, USA
    Am J Health Syst Pharm 58:1734-9. 2001
    ..The total cost of the program was $40,644 in the first year, and there was a net saving thereafter. Therapeutic interchange between pravastatin and simvastatin increased the number of patients meeting their LDL cholesterol goal...
  2. ncbi request reprint The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin
    Matthew K Ito
    Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    Ann Pharmacother 38:277-85. 2004
    ..To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome...
  3. ncbi request reprint Advances in the understanding and management of dyslipidemia: using niacin-based therapies
    Matthew K Ito
    University of the Pacific, Thomas J Long School of Pharmacy and Health Sciences, 3350 La Jolla Village Drive, San Diego, CA 92161 0002, USA
    Am J Health Syst Pharm 60:S15-21; quiz S25. 2003
    ..With recently broadened treatment recommendations, it seems likely that combination therapy will be increasingly deemed the appropriate choice for addressing a range of lipid abnormalities...
  4. ncbi request reprint Fenofibrate and warfarin interaction
    M A Aldridge
    University of Pacific, Stockton, California, and Veterans Administration San Diego Healthcare System, USA
    Pharmacotherapy 21:886-9. 2001
    ..To minimize the risk of supratherapeutic INR values and/or hemorrhagic events, clinicians should perform serial monitoring of INR when initiating fenofibrate therapy in a patient previously stabilized on a coumarin anticoagulant...
  5. ncbi request reprint The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1
    M K Ito
    University of the Pacific School of Pharmacy, Stockton, USA
    J Clin Pharmacol 41:779-82. 2001
    ..2 ng/mL, p = 0.15) or at 10 weeks (51.1 +/- 32.5 vs. 63.9 +/- 26.9 ng/mL, p = 0.44). These data suggest that the conversion from simvastatin to atorvastatin does not adversely affect PAI-1 plasma concentrations in patients with CAD...
  6. ncbi request reprint The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events
    M K Ito
    Department of Pharmacy Practice, School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    J Cardiovasc Pharmacol Ther 6:129-35. 2001
    ..04 to 8.6; P=0.04) were significantly greater compared to patients meeting their LDL cholesterol goal. CONCLUSIONS: Our study results support reducing LDL cholesterol to at least 100 mg/dL in the patient with CHD...
  7. ncbi request reprint Colesevelam hydrochloride: a novel bile acid-binding resin
    M A Aldridge
    School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    Ann Pharmacother 35:898-907. 2001
    ..Since colesevelam is formulated as a tablet, problems with palatability such as with the powder formulation of the bile acid-binding resins are likely to be eliminated...
  8. ncbi request reprint Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
    Matthew K Ito
    University of California, San Diego School of Medicine, La Jolla, California, USA
    Pharmacotherapy 26:85S-97S; discussion 98S-101S; quiz 106S-108S. 2006
    ....
  9. ncbi request reprint Niacin-based therapy for dyslipidemia: past evidence and future advances
    Matthew K Ito
    Southern California Clinical Experience Program, Thomas J Long School of Pharmacy, University of the Pacific, Stockton, USA
    Am J Manag Care 8:S315-22. 2002
    ..Other combination products are currently undergoing clinical testing...
  10. ncbi request reprint Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia
    Eric K Gupta
    University of the Pacific Thomas J Long School of Pharmacy and Health Sciences, Stockton, California, USA
    Heart Dis 4:124-37. 2002
    ..In this review, we will use "extended-release" to refer to the FDA approved slowly dissolving niacin preparation and "sustained-release" to refer to the nutritional supplements (not FDA approved)...
  11. ncbi request reprint Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies
    Robert L Talbert
    College of Pharmacy, University of Texas at Austin, USA
    Am J Health Syst Pharm 60:S22-4; quiz S25. 2003
  12. ncbi request reprint Acute coffee ingestion does not affect LDL cholesterol level
    Rebecca J Cheung
    Thomas J Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
    Ann Pharmacother 39:1209-13. 2005
    ..It is unknown whether coffee consumed prior to drawing blood samples will impact fasting serum lipids...
  13. ncbi request reprint Omacor effects on serum lipids and clinical outcome
    Matthew K Ito
    Am J Cardiol 99:145. 2007